A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

339

Participants

Timeline

Start Date

January 8, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Breast Cancer

Interventions

DRUG

Hemay022+AI

hemay022：orally once daily，A 21-day cycle

DRUG

Lapatinib+Capecitabine

Take the pills according to the instructions

Trial Locations (1)

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Tianjin Hemay Pharmaceutical Co., Ltd

INDUSTRY